Forty Seven Inc. is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a \'don\'t eat me\' signal that cancer cells commandeer to avoid being ingested by the immune system. This antibody is currently being evaluated in two Phase 1 clinical studies in patients with solid tumors and in patients with acute myeloid leukemia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/24/16 | $75,000,000 | Series A |
Clarus Ventures Sutter Hill Ventures | undisclosed |
| 10/18/17 | $75,000,000 | Series B |
Clarus Ventures Sutter Hill Ventures Wellington Management Company  | undisclosed |
